急性冠脉综合征患者pentraxin-3与凝血酶活化的纤溶抑制物的变化

目的了解急性冠脉综合征(Acute Coronary Syndrome,ACS)患者炎性指标pentraxin-3与纤溶指标凝血酶活化的纤溶抑制物(Thrombin activatable finolysis inhibitor,TAFI)的变化。方法检测比较102例急性心肌梗死(AMI组)、81例不稳定心绞痛(UAP组)及23例健康体检者(对照组)的血浆pentraxin-3、TAFI水平。结果急性冠脉综合征患者血浆pentraxin-3、TAFI明显高于对照组,差异有统计学意义(P<0.01);AMI组血浆pentraxin-3及TAFI水平高于UAP组,差异有统计学意义(P<0.05)。pentraxin-3浓度与TAFI浓度呈正相关(r=0.17,P<0.05)。结论 pentraxin-3与TAFI共同在ACS的发生发展中起重要作用。

The Changes of Pentraxin-3 and Thrombin Activatable Fibrinolysis Inhibitor in Patients with Acute Coronary Syndrome

Objective To investigate the expression of inflammatory indicator pentraxin-3 and finolysis indicator Thrombin activatable fibfinolysis inhibitor （TAFI） in the patients with acute coronary syndrome. Methods 102 patients with acute myocardial infarction, 81 patients with unstable angina and 23 controls were studied. All of their bloods were extracted in the early morning. Then we checked their plasma pentraxin-3, TAFI level. Results The plasma pentraxin-3, TAFI level in the patient with acute coronary syndrome were higher than ones in controls（P 〈 0.01 ）. The plasma pentraxin-3, TAFI level in the patients with acute myocardial infarction were higher than ones in the patients with unstable angina （ P 〈 0.05）. The plasma pentraxin-3 is positive correlation to plasma TAFI （ P 〈 0.05）. Conclusions Inflammator~ indicator pentraxin-3 and finolysis indicator TAFI are related to acute coronary syndrome. And the two factors influence each other; and they may work together to promote the occurrence of acute coronary syndrome.